The optimization of processes for the development and manufacture of biopharmaceuticals is pivotal for producing quality products. The development and production of biologics can be a complex process.

LIVINGSTON, UNITED KINGDOM--(Marketwired - Nov 29, 2016) - memsstar Limited announced today that it has installed two ORBIS ALPHA systems in Bosch's German research and development facility in ...

Semiconductor logic and memory technology development continues to push the limits of process complexity and cost, especially as the industry migrates to the 5 nm node and beyond. Optimization of the ...

Continuous manufacturing and a quality-by-design development approach are a natural fit. FDA, as well as other regulatory agencies around the world, have for many years been encouraging drug makers to ...

Cibus, Inc. announced significant advancements in its gene editing technology, particularly the establishment of production standards for its proprietary RTDS gene editing system, which enables the ...

With the FDA expecting to approve 10–20 Cell and Gene Therapies (CGTs) annually by 2025, it is evident that the field will continue to hold immense commercial and medical opportunities. To harness ...

Upstream Process Development (UPD) is essential to ensure robust, scalable processes that can efficiently bring biotherapeutics to market. However, challenges such as optimizing yield, ensuring ...

AI could review data sets to assist clinical scientists ...

As construction costs remain elevated and project timelines grow more difficult to predict, developers are rethinking not only what they build but how they deliver projects to market. In South Florida ...